LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma AG today announced it has entered into an agreement with Pfizer Inc. for the future marketing and commercialization of human prothrombin complex concentrate (PCC), an investigational agent currently under FDA review for the urgent reversal of Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients who require urgent surgery or invasive procedures. Under the terms of the agreement, Octapharma AG has exclusive rights to commercialize this product globally, with the exception of the U.S. where Pfizer will exclusively be responsible for marketing and commercialization.
Help employers find you! Check out all the jobs and post your resume.
